Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.

CONCLUSION: Combined elevation of TRIB2 and MAP3K1 could be novel prognostic biomarkers and potential therapeutic targets to evaluate the malignancy and long-term outcomes of GBM.
PMID: 31318172 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - July 17, 2019 Category: Neuroscience Authors: Wang J, Zuo J, Wahafu A, Wang MD, Li RC, Xie WF Tags: CNS Neurosci Ther Source Type: research